Related Experiment Videos

Cellular mechanisms for the treatment of chronic heart failure: the nitric oxide- and adenosine-dependent pathways

Tetsuo Minamino1, Masafumi Kitakaze

  • 1Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.

Expert Opinion on Emerging Drugs
|July 2, 2005
PubMed

Insights

Drugs improving chronic heart failure (CHF) survival enhance nitric oxide (NO) and adenosine pathways. Targeting these pathways offers a new therapeutic strategy for CHF treatment.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Chronic heart failure (CHF) treatments improving survival often target endogenous nitric oxide (NO) and adenosine pathways.
  • Existing evidence links renin-angiotensin-aldosterone and beta-adrenergic antagonists to enhanced NO-dependent pathways.
  • Carvedilol, amlodipine, and dipyridamole demonstrate effects on cardiac adenosine levels, with dipyridamole associated with CHF improvement.

Purpose of the Study:

  • To explore the role of endogenous nitric oxide (NO) and adenosine in chronic heart failure (CHF).
  • To propose enhancement of NO and/or adenosine pathways as a novel therapeutic strategy for CHF.

Main Methods:

  • Review of existing evidence on drug mechanisms in CHF.
  • Analysis of the cardiovascular effects of nitric oxide (NO) and adenosine.
  • Investigation of the modulation of neurohormonal systems by NO and adenosine in CHF.

Main Results:

  • Drugs improving CHF survival enhance nitric oxide (NO) and/or adenosine pathways.
  • Both NO and adenosine induce vasodilation, decrease myocardial hypercontractility, and reduce myocardial ischemia.
  • NO and adenosine are implicated in the cardioprotection of ischemic preconditioning and modulate CHF-related neurohormonal systems.

Conclusions:

  • Enhancing endogenous nitric oxide (NO) and/or adenosine pathways represents a promising therapeutic target for chronic heart failure (CHF).
  • This approach offers a potential new strategy for the treatment of CHF.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...